Review On Mouth Dissolving Tablet


Published on

This presentation include methods of formulation of MDT. Various preformulation studies conducted & IPQC test.

Published in: Education, Technology, Business
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Review On Mouth Dissolving Tablet

  1. 1. Review: On Mouth Dissolving Tablet Presented By S. B. THOKE [M. PHARM] [DEPT OF PHARMACEUTICS]
  2. 2. Content’s - Definition Significance Requirements of ODTs Formulation Methodologies Patented Technologies Superdisintegrants employed in ODT Evaluation References 2
  3. 3. DefinitionFast Dissolving Tablets (FDTs) or “mouth dissolvingtablets” (MDTs) which disintegrates or dissolvesrapidly without water within few seconds in themouth. 3
  4. 4. According to European pharmacopoeia, these MDTsshould dissolve/disintegrate in less than three minutes.US FDA defined ODTs as “A solid dosage formcontaining medicinal substances or active ingredientswhich disintegrates rapidly within a few seconds whenplaced up on tongue” 4
  5. 5. Mouth dissolving tablets are also called as Orodispersible tablets (ODTs), Fast disintegrating tablets, Orally disintegrating tablets, Quick disintegrating tablets, Fast dissolving tablets, Rapid dissolving tablets, Porous tablets, Quick melt tablets & Rapid melt tablets. 5
  6. 6. Significance It offer all advantages of solid dosage forms and liquid dosage forms along with special advantages, includes It provide good stability, accurate dosing, easy manufacturing, small packaging size & easy to handle. No need of water to swallow the dosage form. Easy to administer for paediatric, geriatric & institutionalized patients. More rapid drug absorption from the pre- gastric area which may produce Quick onset of action. 6
  7. 7.  Pre-gastric absorption of drug avoids hepatic metabolism, which reduces the dose and increase the bioavailability. The risk of chocking or suffocation during oral administration avoided. Good mouth feel property of MDDDS helps to change the basic view of medication as "bitter pill" Patient’s compliance for disabled bedridden patients and for travelling and busy people, who do not have ready access to water. 7
  8. 8. Requirements of ODTsAn ideal FDT shouldI. Dissolve / disintegrate in the mouth in matter of seconds without water.II. Have sufficient mechanical strength and good package design.III. Not affected by drug properties.IV. Effective taste masking technologies should be adopted for bitter taste drugs.V. Leave minimal or no residue in mouth after oral administration.VI. Exhibit low sensitivity to environment condition such as humidity and temperature. 8
  9. 9. Formulation Methodologies 1. Freeze drying or lyophilization 2. Molding 3. Cotton candy process 4. Spray drying 5. Mass extrusion 6. Nanonization 7. Three-dimensional Printing (3DP) 8. Compaction i) Melt granulation j) Phase transition process k) Sublimation 9
  10. 10. 9. Conventional methodsb)Dry granulationc)Wet granulationd)Direct compression 10
  11. 11. 1. Freeze drying or lyophilizationThis process includes the removal of solvent from afrozen suspension or solution of drug withstructure-forming additives.Freeze-drying of drug along with additives impartsglossy amorphous structure resulting in highlyporous and lightweight product.MDTs formed by lyophilization have low mechanical strength, poor stability at higher temperature, and humidity 11
  12. 12. 2. MoldingMolded tablets are prepared by using water-solubleingredients.The powder blend is moistened with ahydroalcoholic solvent.Molded into tablets under pressure lower than thatused in conventional tablet compression.Solvent is then removed by air-drying.Molded tablets are very less compact thancompressed tablets. 12
  13. 13. 3. Cotton candy processThis process involves formation of matrix ofpolysaccharides or saccharides by simultaneousaction of flash melting and spinning.Formed matrix is partially re-crystallized to haveimproved flow properties and compressibility.This candy floss matrix is then milled.Blended with active ingredients and excipients andsubsequently compressed to FDTs. 13
  14. 14. 4. Spray dryingIn this method hydrolyzed and nonhydrolyzedgelatin were used as supporting matrix.Mannitol as bulking agentSodium starch glycolate or crosscarmellose sodiumas superdisintegrant.Acidic substances (citric acid) or alkali substance(sodium bicarbonate) further increasedisintegration and dissolution. 14
  15. 15. This technology produces highly porous and finepowders as processing solvent is evaporated duringprocess.Disintegration time < 20 sec 15
  16. 16. 5. Mass extrusionInvolves softening the active blend using thesolvent mixture of water-soluble polyethyleneglycol and methanol.Subsequent expulsion of softened mass through theextruder or syringe.To get a cylinder of the product into evensegments using heated blade to form tablets. 16
  17. 17. 6. NanonizationNanomelt technology involves reduction in theparticle size of drug by proprietary wet-millingtechnique.Nanocrystals of the drug are stabilized againstagglomeration by surface adsorption on selectedstabilizers, which are then incorporated into MDTs.AdvantagesFor poor water soluble drugs.Fast disintegration/dissolution ofnanoparticles . .. leads to increased absorption andbioavailability.Reduction in dose. 17
  18. 18. 7. Three-dimensional Printing (3DP)It is a rapid prototyping (RP) technology.Prototyping involves constructing specific layersthat uses powder processing and liquid bindingmaterials.Loose powders in it was fabricated using 3DPprocess.Based on computer-aided design modelsTAG tablets seemed due to the rapid waterpenetration into the tablet resulting from the largepore size 18
  19. 19. 8. Compactiona) Melt granulationPowders are efficiently agglomerated by a melt ablebinder.Advantages:- No water or organic solvents isneeded.For this, purpose high shear mixers are utilized.Product temperature is raised above the meltingpoint of binder by a heating jacket or by the heat offriction generated by impeller blades. 19
  20. 20. It involves the use of a hydrophilic waxy binder(Superpolystate©, PEG-6-stearate).Superpolystate© having melting point 33–37°C anda HLB value 9.So it will not only act as a binder but will also helpthe disintegration. 20
  21. 21. b) Phase transition processIn this compress powder containing erythritol(melting point: 122 °C) and xylitol (melting point:93 - 95 °C), and then heating at about 93 °C for 15min.After heating, the median pore size and tablethardness was increased.Heating process enhances the bonding amongparticles leads to sufficient hardness of tablets. 21
  22. 22. c) SublimationWhen inert volatile solid ingredients likeammonium bicarbonate, ammonium carbonate,benzoic acid, camphor, hexamethylene tetramine,naphthalene, phthalicanhydride, urea and urethanewere added to other tablet excipients.Blend was compressed in to a table & finallysubjected to sublimation resulting in highly porousstructures.Tablets produce by this method exhibit good mechanical strengthhigh, porosity (approximately 30%), dissolved within 15 seconds in saliva. 22
  23. 23. Figure:- Steps Involved in sublimation 23
  24. 24. 9. Conventional methodsa) Direct compressionEasiest way to manufacture tablets.Conventional equipment, commonly availableexcipients and a limited number of processing stepsare involved in direct compression.Also high doses can be accommodated and finalweight of tablet can easily exceed that of otherproduction methods.Tablet disintegration time can be optimized byconcentrating the disintegrants. 24
  25. 25. Below critical concentration, tablet disintegrationtime is inversely proportional to disintegrantsconcentration.Above the critical concentration level,disintegration time remains approximately constantor even increases.The major drawback of effervescent excipients istheir hygroscopicity (i.e., the ability to absorbatmospheric moisture).Another approach is the use of sugar‐basedexcipients (e.g., dextrose, fructose, isomalt,maltitok, maltose, mannitol, sorbitol, starchhydrolyse, polydextrose, and xylitol). 25
  26. 26. Which are having high aqueous solubility andsweetness.It impart taste masking and a pleasing mouthfeel.Microcrystalline cellulose, cross linkedcarboxymethyl cellulose sodium, cross linkedpolyvinyl pyrrolidone and partially substitutedhydroxypropyl cellulose, though water insoluble,absorb water and swell due to capillary action andact as effective disintegrants. 26
  27. 27. b) Wet granulationAcid component of the effervescent couplepresented in the tablet with lower than 5%, quickdisintegration times could be achieved.In the patent, the formulation includes polyalcohols(e.g., mannitol, xylitol, sorbitol, maltitol, erythritol,and lactitol).1–30% of an edible acid & an active ingredient asthe dry mixture wet granulated with an aqueoussolution of a water-soluble or water-dispersiblepolymer (e.g., poly(ethylene glycols), carrageenan,and ethylcellulose). 27
  28. 28. which consisted of 1–10% of the final weight ofthe granule in a fluid bed.Granules with high porosity and low apparentdensity disintegration times ranging from 3 to 30seconds in the saliva were obtained. 28
  29. 29. c) Dry granulationLow-density alkali earth metal salts or water-soluble carbohydrates were precompacted, and theresulting granules were compressed into tablets.Powdered material with a density of 0.2–0.55g/mL was precompacted to increase the density to0.4–0.75 g/mL by applying a force ranging from 1to 9 kN/cm.The resulting granules were compressed intotablets. 29
  30. 30. Patented Technologies1. OraSolv technologyOraSolv technology (Cima Labs) produces tabletsby low compression pressureIt uses an effervescent disintegration pair thatreleases gas upon contact with water.Widely used effervescent disintegration pairs Acid sources Carbonate sourcesCitric acid, Tartaric acid, Sodium bicarbonate,Malic acid, Fumaric Sodium carbonate,acid, Adipic acid, and Potassium bicarbonate,Succinic acids. and Potassium carbonate. 30
  31. 31. The carbon dioxide evolved from the reaction mayprovide some “fizzing” sensation, which is apositive organoleptic sensation.20–25% of total weight of tablet effervescent agentis used.OraSolv tablets - soft and fragile nature.PakSolv - Special packaging system “Dome-shaped” blister package Prevents the vertical movement of the tabletwithin the depressions. Protect the tablets from breaking during transportand storage also offers light, moisture, and childresistance. 31
  32. 32. 2. DuraSolv TechnologyDeveloped by Ciba, second-generation technology.To Produce stronger tablets for packaging inblisters or bottles.Tablets have low friability, about 2% or less whentested according to the USP.Hardness of the tablets - at least about 15–20 N.Disintegration time is less than 60 seconds.By Direct compression method tablets produce.conventional tableting methodologies & conven-tional package equipment are used. 32
  33. 33. Key ingredients - Non-direct compression filler and lubricant.Non-direct compression filler - particle size 20-65 μm. e.g. dextrose, mannitol, sorbitol, lactose, &sucrose. advantage - quick dissolution and avoid gritty orsandy texture. 60–95% amount of the total tablet weight is used.Direct compressible fillers – at least 85% of the particles are over 100 μm size. Have some of the gritty or sandy texture. 33
  34. 34. Higher amounts (1–2.5%) of hydrophobiclubricants, such as magnesium stearate, can beadded.lubricant blending times can also be increased to10–25 minutes or longer.0.2–1% lubricant in conventional tablets.Relatively modest compressive force is needed tocompress the formulation. 34
  35. 35. 3. WOWTAB TechnologyPatented by "Yamanouchi Pharmaceutical Co. "WOW means "Without Water ".In this process, API is mixed with a lowmouldability saccharide and granulated with a highmouldability saccharide and compressed intotablet.There is no single saccharide that can make tabletshaving both high strength and fast disintegrationproperties. 35
  36. 36. Low moldability saccharidese.g. lactose, mannitol, glucose, sucrose, andxylitol.Tablets with hardness 0-2 kg, when 150 mg ofsuch a saccharide is compressed under pressure of10–50 kg/cm2 using a die 8 mm in diameter.High-moldability saccharidese.g. maltose, oligosaccharides, maltitol, & sorbitol.Produce tablets with hardness above 2 kg whenprepared under identical conditions.The typical high- moldability saccharides are 36
  37. 37. 4. Flashtab TechnologyPrographarm laboratories have patented theFlashtab technology.Drug micro granules may be prepared by using theconventional techniques like coacervation, microencapsulation, and extrusion spheronisation.Excipients mixtureis prepared by either dry or wetgranulation methods.Excipients used - two groups of components:1] Disintegrating agents- carboxymethylcelluloseor insoluble reticulated polyvinylpyrrolidone; and 37
  38. 38. 2] Swelling agents- carboxymethylcellulose,starch, modified starch, carboxymethylatedstarch, microcrystalline cellulose, and possiblydirectly compressible sugars. 38
  39. 39. 5. AdvaTab TechnologyPatented by Kyowa Hakko KogyoLubrication is dispensed onto each tablet by usinga spray.10–30 times less hydrophobic lubricant employed& 30–0% stronger than conventional tablets.Handle high drug loading and coated drugparticles.Traditional tablets produced using an internallubrication system, which disperses lubricant onthe inside and the surface of the tablets, decreasetablet mechanical strength. 39
  40. 40. 6. Dispersible Tablet TechnologyLek in Yugoslavia was issued patents fordispersible tablets of dihydroergotoxine andcimetidineDihydroergotoxine is poorly water soluble in freebase form.Improved dissolution rate of dihydroergotoxinemethanesulphonate was observed with dispersibletablets containing 0.8– 10%, preferably about 4%by weight, of an organic acids. 40
  41. 41. Cimetidine formulated with one of disintegratingagent. It provides rapid swelling and/or goodwetting capability to the tablets and thereby a quickdisintegration.Disintegrating agentse.g. starch or modified starches, microcrystallinecellulose, alginic acid, cross-linked sodiumcarboxymethyl cellulose, and cyclodextrinpolymers.Combination of two or more disintegrating agentsproduced better disintegration results. 41
  42. 42. 7. Pharmaburst TechnologyProcess involves a dry blend of a drug, flavor, andlubricant that are compressed into tablets on astandard tablet press with stock tooling.uses off- the-shelf coprocessed excipients,depending on the type of active and loading (up to700mg), dissolves within 30–40 seconds.Manufacture process can be carried out undernormal temperature and humanity conditions.The tablets can be packaged in blister packs orbottle. 42
  43. 43. 8. OraQuick technologyIt utilizes a patented taste masking technology.KV Pharmaceutical claims its microspheretechnology, known as MicroMask.Taste masking process does not utilize solvents ofany kind, it leads to faster and more efficientproduction.Lower heat of production than alternative fast‐dissolving/disintegrating technologies makesOraQuick appropriate for heat‐sensitive drugs.Matrix that surrounds and protects the drugpowder in microencapsulated particles is morepliable. 43
  44. 44. Tablets can be compressed to achieve significantmechanical strength without disrupting tastemasking.KV Pharmaceutical has products in developmentsuch as analgesics, scheduled drugs, cough andcold, psychotropics, and anti‐infectives 44
  45. 45. 9. Quick –Dis technologyLavipharm Laboratories Inc. (Lavipharm) inventedthis ideal intraoral FDDS.Thin, flexible, and quick‐dissolving film.Quick‐Dis™ provided in various packagingconfigurations, unit‐dose pouches to multiple‐doseblister packages.Film with a thickness of 2 mm have disintegrationtime 5 to 10 seconds & dissolving time, is around30 seconds.Typical release profile of API is 50% releasedwithin 30 seconds and 95% within 1 minute. 45
  46. 46. 10. Zydis technologyZydis is a unique freeze dried oral solid dosageform.Dissolves in less than 3 seconds.Drug is physically trapped in a water solublematrix, and then freeze dried.Thirteen products are currently available based onzydis technology. In worldwide market, zydis formulations available for oxazepam, lorazepam, loperamide, and enalapril. 46
  47. 47. Matrix contain excipients like1] Polymers (e.g., gelatine, alginates, and dextrin)to provide strength and rigidity to tablets;2] Polysaccharides (e.g.,mannitol and sorbitol)to impart crystallinity and hardness to the matrixand to improve palatability;3] Collapse protectants (e.g, glycin)to prevent the product from shrinking in itspackaging during manufacturing or storage;4] Flocculating agents (e.g, xanthan gum andacacia)to provide uniform dispersion of drug particles;5] Preservatives(e.g., parabens)to prevent microbial growth; 47
  48. 48. 6] Permeation enhancers (e.g., sodium laurylsulphate)to improve transmucosal permeability;7] pH adjusters (e.g, citric acid)to optimize chemical stability;8] Flavours and sweetenersto improve patient compliance and9] water to ensure formation of porous units.In US, zydis products available-Claritin Reditab, Dimetapp Quick Dissolve,Feldene Melt, Maxalt-MLT, Pepcid RPD, ZofranFDT, and Zyprexa Zydis. 48
  49. 49. 11. Frosta technologyPatented by Akina.It utilizes core concept of formulating plasticgranules and compressing at low pressure toproduce strong tablets with high porosity.Process involves mixing the porous plasticmaterial with water penetration enhancer andgranulated with binder.Used for - aspirin, loratidine, caffeine, and folicacid, vitamins and dietary supplements. 49
  50. 50. Superdisintegrants employed in ODT Super Commercially Mechanism of Specialdisintegrants available grades action commentCrosslinked Crosscarmellose® Swells 4-8 folds in Swells in twoCellulose Ac-Di-Sol®, < 10 seconds. dimensions. Nymce ZSX® Swelling and Direct Primellose®, wicking both. compression or Solutab®, Granulation Vivasol®, L-HPC Starch free.Crosslinked Crosspovidon M® Swells very little Water insolublePVP Kollidon® and returns to and Polyplasdone® original size after spongy in nature compression but act so get porous by capillary action. tablet. 50
  51. 51. Crosslinked Explotab® Swells 7-12 folds in Swells in threestarch Primogel® < 30 seconds. dimensions and high level serve as sustain release matrix.Crosslinked Alginic acid Rapid swelling in Promotealginic NF aqueous medium or disintegrationAcid wicking action. in both dry or wet granulation.Soy Emcosoy® Does not containPolysaccharides any starch or Sugar. Used in Nutritional products.Calcium silicate Wicking action Highly porous, Light weight. 51
  52. 52. Marketed product of MDTsBrand name Active ingredient Application companyClaritin® Loratadine Antihistamine ScherigRediTabs® corporationFeldene Melt® Piroxicam NSAIDs PfizerMaxalt® -MLT® Rizatritpan Migrane Merck benzoatePepeid® ODT Femotidene Anti-ulcer MerckZyperxa® Olazepine Psychotropic Eli LillyZofran® ODT Olandansetron Antiemetic Galaxo Smith klineResperdal® M- Resperidone Schizophrenia JanssenTab TMKlonopin® wafer Clonazepam Sedation RocheImodium Istant Loperamide HCL Antidiarrheal JannsenMeltsNasea OD Ramosetoron HCl Anti-emetic YamanouchiTempra Acetaminophen Analgesic Bristol-MQuicksolv® ters squibb 52
  53. 53. Preformulation Studies1. Bulk DensityFormulaWhere :ρb - Bulk density, M- Weight of powder, andV- Volume of powder.2. Tapped DensityFormula ρt = M / VtWhere :ρt - Tapped density, M- Weight of powder, andVt- Minimum volume occupied after tapping. 53
  54. 54. 3. Compressibility IndexSimplest way for measurement of flow of powder.Formula % C.I. = ρt – ρb/ρt x1004. Hausner ratio Hausner ratio is an indirect index of ease of powder flow. Lower the value of Housner ratio better is the flow property. Formula Hausner ratio = ρt/ ρb 54
  55. 55. Flow property % C.I. Hosner ratio Excellent ≤10 1.00-1.11 Good 11-15 1.12-1.18 Fair 16-20 1.19-1.25 Passable 21-25 1.26-1.34 Poor 26-31 1.35-1.45 Very poor 32-37 1.46-1.59 Very, very >38 >1.6 poor 55
  56. 56. 5. PorosityFormula ε = ( 1 - ρapp / ρtrue) X 100Where,ε- Porosity, ρapp- Apparent density, andρtrue- True density.6.Voide Volume Formula V = Vb - Vp Where, V- Voide volume, Vb- Bulk volume, and Vp- Tapped volume. 56
  57. 57. 7. Angle of reposeFormula ϴ = Tan-1 ( h / r )Where,ϴ- Angle of repose, h- Hight of the heap, andr- Radius of the heap. Flow property Angle of repose (degrees) Excellent 25-30 Good 31-35 Fair- aid not needed 36-40 Passable- must agitate, 41-45 vibrate Poor 46-55 Very poor 56-65 Very, very poor >66 57
  58. 58. Evaluation of Mouth dissolving1. ThicknessMeasured using Vernier calipers.2. HardnessForce required to break a tablet by compression inthe radial direction.Pfizer hardness testers Monsanto hardness tester. 58
  59. 59. 3. Uniformity of weight20 tablets randomly take from lot and weightedindividually to check for weight variation. Weight variation specification as per IP Average weight of tablet % Deviation 80 mg or less ±10 More than 80 mg but less than ±7.5 250 mg 250 mg or more ±5 59
  60. 60. 4. In-vitro dispersion time testDrop a tablet in a beaker containing 50ml ofsorrenson’s buffer pH 6.8 & time required forcomplete dispersion was determined. 60
  61. 61. 5. Friability testDetermined using Roche friability.Subjected to 100 revolutions (25rpm/minute).Formula f = (1- W0 / W) × 100Where,f- Friability, W0- Weight of the tablets before, andW- Weight of the tablet after the test.6. In vivo Disintegration timeTime required for complete disintegration oftablets in oral cavity determined by administeringtablets to 10 healthy volunteers. 61
  62. 62. 7. Wetting timeTablet is placed on a piece of tissue paper foldedtwice and kept in a Petri dish (ID = 6.5 cm)containing 6 ml of water, and the time for completewetting is measured.8. Water absorption ratio This test performed as like wetting time Formula R = 10 ( Wa /Wb) Where, R- Water absorption ratio, Wb- Weight of tablet before water absorption, & Wa- weight of tablet after water absorption. 62
  63. 63. 9. Dissolution testDissolution study performed using USP IIapparatus (paddal speed 50rpm).USP monographs dissolutions conditions shouldbe followed in addition 0.1N HCl, pH 4.5 & 6.8buffers should be evaluated.10. Stability studyAs per ICH Q1A guidelines for acceleratedstudies.Tablets stored at 40±1ºC/75% ± 5% RH for 4weeks. 63
  64. 64. Afterword withdraw & analyse for physicalcharacterization (visual defects, hardness,friability, disintegration, dissolution etc.) drugcontent. 64
  65. 65. Promising Drugs to be incorporated In FDTAnalgesics and Anti-inflammatory AgentsAnti-Arrhythmic AgentsAnti-bacterial AgentsAnti-coagulantsAnti-EpilepticsAnti-Fungal AgentsAnti-Gout AgentsAnti-Hypertensive AgentsAnti-MalarialsAnti-Neoplastic Agents And ImmunosuppressantsAnti Protozoal AgentsAnti-Muscarinic AgentsAnti-Parkinson Agents 65
  66. 66. Gastro-Intestinal AgentsHistamine H,-Receptor AntagonistsStimulantsLipid Regulating AgentsLocal AnaestheticsNeuro -Muscular AgentsNitrates And Other Anti-Anginal AgentsNutritional AgentsOpioid AnalgesicsOral VaccinesProteins, Peptides And Recombinant DrugsSex HormonesAnti-Thyroid AgentsAnxiolytic, Sedatives, Hypnotics And NeurolepticsTj-Blockers 66
  67. 67. Cardiac Inotropic AgentsCorticosteroidsEnzymesDiuretics 67
  68. 68. References Prashant B Pawar, “MOUTH DISSOLVING TABLET: A REVIEW”,International Journal of Herbal Drug Research, Vol I, Issue II;2011, Pageno.- 22-29.Debjit Bhowmik, “Fast dissolving tablet: A review on revolution ofnovel drug delivery system and new market opportunities” ScholarsResearch Library, Der Pharmacia Lettre, 1 (2); 2009, Page no.- 262-276. Alok Kumar Gupta, “Fast Dissolving Tablet- A Review”, The PharmaInnovation, Vol. 1(1); 2012, ISSN 2277-7695, Page no.- 1- 7. V. Dinesh kumar, “A comprehensive review on fast dissolving tablettechnology”, Journal of Applied Pharmaceutical Science, 01 (05); 2011,ISSN: 2231-3354, Page no.- 50-58. A. Gupta, “Recent Trends of Fast Dissolving Tablet - An Overview ofFormulation Technology”, International Journal of Pharmaceutical &Biological Archives, 1(1); 2010, Page no.- 1-10. 68
  69. 69.  Velmurugan S., “Oral Disintegrating Tablets: An Overview”,International Journal of Chemical and Pharmaceutical Sciences, Vol.1 (2);Dec. 2010, Page no.- 1-12. P. Ashish, “A Review- Formulation of Mouth Dissolving tablet”,International Journal of Pharmaceutical and Clinical Science, 1 (1); 2011,Page no.- 1-8. Bhupendra G Prajapati, “A Review on Recent patents on FastDissolving Drug Delivery System”, International Journal of Pharm TechResearch CODEN( USA): IJPRIF ISSN : 0974-4304, Vol.1, No.3; July-Sept 2009, Page no.- 790-798. Mukesh P. Ratnaparkhi, “Review On: Fast Dissolving Tablet”, Journalof Pharmacy Research, Vol.2, Issue 1; January 2009, Page no.- 5-12. Tejvir Kaur, “Mouth Dissolving Tablets: A Novel Approach To DrugDelivery”, International Journal of Current Pharmaceutical Research,ISSN- 0975-7066, Vol 3, Issue 1; 2011, Page no.- 1-7. Jaysukh J Hirani, “Orally Disintegrating Tablets: A Review”, TropicalJournal of Pharmaceutical Research, 8 (2); April 2009, Page no.- 161-172 69
  70. 70. Thank u…! 70